Entries by Dan Zapata

La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis

– Treatment with LJPC-401 Resulted in Statistically Significant Reduction in Change in Transferrin Saturation (TSAT), the Primary Efficacy Endpoint of the Study, and Frequency of Phlebotomies, a Key Secondary Efficacy Endpoint of the Study – SAN DIEGO, CA – June 6, 2019 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development […]

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress

SAN DIEGO, CA – May 6, 2019 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress. For the […]

La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria

-Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from severe malaria- – NDA Planned for LJPC-0118 for Fourth Quarter of 2019 – SAN DIEGO, April 24, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and […]

La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer

SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Darryl Wellinghoff as Chief Commercial Officer. “We are excited to welcome Darryl to La Jolla’s leadership team,” said George Tidmarsh, M.D., […]

La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, […]

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018

SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2018. For the three months ended September 30, 2018, GIAPREZA™ (angiotensin II) net […]

La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018

SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will release its third quarter 2018 financial results on Wednesday October 24, 2018 and will host a webcasted conference call at 4:30 […]

La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA

SAN DIEGO – August 3, 2018 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for […]

La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018

SAN DIEGO – August 1, 2018 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will release its second quarter 2018 financial results on Wednesday, August 8, 2018 and will host […]